分化型高级别甲状腺癌的诊断考量与临床特征
该研究回顾了2012至2022年单中心32例分化型高级别甲状腺癌(DHGTC)的细胞学、组织学、治疗及结局,并系统综述2013至2023年英文文献。结果显示DHGTC罕见但侵袭性强,常表现为高级别特征(坏死、核分裂、Ki67增高)及侵袭行为,需在分化良好的甲状腺肿瘤中加以鉴别以评估复发和预后。
要点
- DHGTC为2022年WHO新定义实体,细胞学多分类为恶性或滤泡性肿瘤。
- 肿瘤平均大小5.15 cm,多数为乳头状癌(87.5%),常见经典亚型。
- 侵袭性特征常见:甲状腺外扩展17例、血管侵犯21例、淋巴结转移10例。
核心结论
- DHGTC是罕见但侵袭性的甲状腺肿瘤亚型,需在分化良好的甲状腺肿瘤中考虑以评估复发和预后。
研究设计与样本
- 单中心回顾性队列纳入2012至2022年诊断的32例DHGTC,并系统综述2013至2023年PubMed和Embase英文文献。
主要发现
- 平均年龄52.6岁(范围17-84岁),男女比1.3:1。
- 细针穿刺细胞学按TBSRTC分类:恶性14例(43.8%)、滤泡性肿瘤10例(31.3%)、意义不明的异型性5例(15.6%)、可疑恶性2例(6.2%)、无诊断性1例(3.1%)。
- 平均肿瘤大小5.15 cm,乳头状癌28例(87.5%),经典亚型最常见。
- 21例有肿瘤坏死,无坏死病例核分裂活性平均5.5个/2 mm²(范围0-7),平均Ki67增殖指数5.6%。
- 甲状腺外扩展17例、血管侵犯21例、淋巴管侵犯7例、神经周围侵犯1例;诊断时淋巴结转移10例,远处转移或局部复发7例;至今25例存活,1例死于疾病。
关键数值与推荐
- TBSRTC分类:恶性43.8%、滤泡性肿瘤31.3%、意义不明的异型性15.6%、可疑恶性6.2%、无诊断性3.1%。
- 无坏死病例核分裂活性平均5.5个/2 mm²(范围0-7),平均Ki67指数5.6%。
临床怎么用
- 对分化良好的甲状腺肿瘤应评估高级别特征(坏死、核分裂、Ki67)以识别DHGTC。
- DHGTC患者需密切随访以监测复发和远处转移。
局限性
- 单中心回顾性设计,样本量有限(32例)。
- 部分病例Ki67为选做免疫组化,可能存在检测偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Differentiated high-grade thyroid carcinomas (DHGTCs) are a new diagnostic entity most recently defined in the 2022 World Health Organization's (WHO) Classification of Endocrine and Neuroendocrine Tumors. This new entity has been minimally described in the literature, and additional cases classified as such are missing. MATERIALS AND METHODS: Cases of DHGTCs diagnosed at our institution from 2012 to 2022 were identified, and the following were reviewed: cytologic and histologic diagnoses, ancillary testing, immunohistochemical staining, treatments, and patient outcomes. Immunohistochemical staining for Ki67 was performed on selected cases lacking this immunostain. A systematic literature review of the English literature on DHGTCs from 2013 to 2023 was performed using PubMed and Embase. RESULTS: Case cohort included 32 cases of DHGTCs, with an average age of 52.6 years (range 17-84 years) and a male:female ratio of 1.3:1. All cases underwent fine needle aspiration (FNA) and were categorized by The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) as follows: 14 cases as malignant (43.8 %), 10 as follicular neoplasm (31.3 %), 5 as atypia of undetermined significance (15.6 %), 2 as suspicious for malignancy (6.2 %), and 1 as non-diagnostic (3.1 %). The average tumor size was 5.15 cm, and most were papillary thyroid carcinoma (28, 87.5 %), with classic subtype being the most common. Twenty-one cases revealed tumor necrosis and the mitotic activity in lesions without necrosis averaged to 5.5 mitoses per 2 mm2 (range 0-7). The average Ki67 proliferative index was 5.6 %. Extrathyroidal extension was seen in 17, angioinvasion in 21, lymphatic invasion in 7, and perineural invasion in 1 case. Foci of solid or trabecular growth were identified in five cases. Lymph node metastases at the time of diagnosis were noted in 10 cases and 7 demonstrated distant metastases or locoregional recurrence. To date, 25 patients are alive, and one has died from disease. CONCLUSIONS: Our institutional experience demonstrates that DHGTC is a rare, but aggressive thyroid tumor subtype that requires consideration in the setting of a well-differentiated thyroid neoplasm to appropriately assess for possible disease recurrence and determination of patient prognosis.
引用
- Tondi Resta I, Gubbiotti MA, Montone KT, et al. Differentiated high grade thyroid carcinomas: Diagnostic consideration and clinical features. Hum Pathol. 2024. PMID: 38244615. doi:10.1016/j.humpath.2024.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。